Continuation of Liraglutide During Fasting Is Not Associated with Hypoglycaemia

  • Rosalie Koot Department of Internal Medicine, Rijnstate Hospital, Arnhem
  • Marcel van Borren Department of Clinical Chemistry, Rijnstate Hospital, Arnhem
  • Hans de Boer Department of Internal Medicine, Rijnstate Hospital, Arnhem


Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, is increasingly used in obese patients with type 2 diabetes mellitus (T2DM) in doses of up to 3.0 mg/day because of its attractive pharmacological profile. It is currently not known how to proceed with this medication during fasting for surgery. Discontinuation is likely to result in hyperglycaemia, while continuation might lead to hypoglycaemia, but, in view of its mode of action, continuation of GLP-1 analogs is likely to be safe. However, as evidence-based guidelines on GLP-1 management during perioperative fasting are not available, the safety of either policy needs to be confirmed on an individual basis. We therefore decided to perform a preoperative assessment of the glucose response to fasting during continuation of GLP-1 before giving a recommendation in individual cases. So far, 12 severely obese T2DM patients scheduled for bariatric surgery have been evaluated preoperatively by measuring glucose and insulin levels during a 32-hour fast with continuation of liraglutide. Hypoglycaemia was not observed. This suggests that liraglutide in doses of up to 3.0 mg can be safely continued during surgery without risking hypoglycaemia.



  • Meloni AR, De Young MD, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diab Obes Metab 2012;15:15–27.

  • Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzveldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) in the fasting state in healthy subjects. Acta Diabetol 1995;32:13–16.

  • Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397–2403.

  • Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE, et al. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf) 2009;71:500–506.

  • Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean MEJ, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liragutide. Int J Obes 2011;36:843-854.

  • Pi-Sunyer X, Astrup A, Fujioka KA, et al. Randomized, controlled trial of 3.0 mg liraglutide in weight management. N Engl J Med 2015;373:11–22.
  • Published: 2017-10-26

    Issue: Vol 4 No 10 (view)

    Section: Articles

    How to cite:
    Koot, R., van Borren, M., & de Boer, H. (2017). Continuation of Liraglutide During Fasting Is Not Associated with Hypoglycaemia. European Journal of Case Reports in Internal Medicine, 4(10).